Beyond telaprevir and boceprevir: Resistance and new agents for hepatitis C virus infection

Topics in Antiviral Medicine

Volumn 20, Issue 4, 2012, Pages 139-145

  Wyles, David L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DRUG DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; TELAPREVIR; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG COMBINATION; GENETICS; HEPATITIS C; HUMAN; METHODOLOGY; MISSENSE MUTATION; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; MUTATION, MISSENSE; OLIGOPEPTIDES; PROLINE; VIRAL PROTEINS;

EID: 84877776880     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827-1838.
2. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839-1850.
3. Poordad F, McCone JJr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
4. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. J Hepatol. 2011;54(Suppl 1):S4.
5. Margeridon S, Pogam SL, Liu TF, et al. No detection of variants bearing NS5B S282T mericitabine (MCB) resistance mutation in DAA treatment-naïve HCV genotype 1 (G1)-infected patients using ultradeep pyrosequencing (UDPS). Hepatology. 2011;54(S1):532A.
6. Lenz O, Fevery B, Vijgen L, et al. TMC435 in combination with peginterferon alpha-2a/ribavirin in treatment-naive patients infected with HCV genotype 1: virology analysis of the PILLAR study. [Abstract 1329.] 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD). November 4-8, 2011; San Francisco, CA.
7. Pauwels F, Mostmans W, Quirynen LM, et al. Binding-site identification and genotype profiling of hepatitis C virus polymerase inhibitors. J Virol. 2007;81(13):6909-6919.
8. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54(6):1924-1935.
9. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216-224.
10. Suzuki F, Ikeda K, Toyota J, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/intolerant to peginterferon. [Abstract 14.] 47th Annual Meeting of the European Association for the Study of the Liver (EASL). April 18-22, 2012; Barcelona, Spain.
11. Sulkowski M, Rodriguez-Torres M, Lawitz E, et al. Interim sustained virologic response rates in treatment-naïve HCV genotype 1a and 1b patients treated for 12 or 24 weeks with an interferon-free all-oral Quad regimen. [Abstract 1421.] 47th Annual Meeting of the European Association for the Study of the Liver (EASL). April 18-22, 2012; Barcelona, Spain.
12. Poordad F, Lawitz E, Kowdley KV, et al. A 12-week interferon-free regimen of ABT-450/r + ABT-333 + ribavirin achieved SVR12 in more than 90% of treatmentnaïve HCV genotype-1-infected subjects and 47% of previous non-responders. [Abstract 1399.] 47th Annual Meeting of the European Association for the Study of the Liver (EASL). April 18-22, 2012; Barcelona, Spain.
13. Gane EJ, Stedman CA, Hyland RH, et al. ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3. [Abstract 1113.] 47th Annual Meeting of the European Association for the Study of the Liver (EASL). April 18-22, 2012; Barcelona, Spain.
14. Gane E, Stedman C, Anderson J, et al. 100% Rapid virologic response for PSI-7977 + ribavirin in genotype 1 null responders (ELECTRON): early viral decline similar to that observed in genotype 1 and genotype 2/3 treatment-naïve patients. [Abstract 54LB.] 19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5-8, 2012; Seattle, WA.
15. Sulkowski MS, Gardiner D, Lawitz E, et al. Potent viral suppression with the all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor), +/-ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2). [Abstract 1422.] 47th Annual Meeting of the European Association for the Study of the Liver (EASL). April 18-22, 2012; Barcelona, Spain.